Short-term Therapy for Acute Myelogenous Leukaemia in Younger Patients
It has now been repeatedly demonstrated that it is possible to achieve complete remission (CR) in the majority of younger adults with acute myelogenous leukaemia (AML) [4, 5, 7, 11, 12], and that approximately one-fifth of patients in whom this is achieved will continue well without recurrence for many years [2, 6, 8, 10]. These observations have naturally stimulated considerable research in to how these achievements may be translated into cure being probable for the majority rather than possible for the minority. In general, the trend has been to increase the quantity of initial therapy to the limits of bone marrow tolerance, which has been considerably extended by the availability of platelet concentrates and powerful broad spectrum antibiotics. In 1978 such an approach was introduced at St. Bartholomew’s Hospital. In the light of there being no convincing evidence that maintenance therapy prolonged remission following very intensive initial treatment, and some (evidence) to the contrary [3, 9], it was decided to limit the duration of the programme to approximately 6 months by terminating all therapy after a maximum of six cycles of adriamycin (adria), cytosine arabinoside (araC) and 6-thioguanine (6-TG) given at approximately 3 weekly intervals.
KeywordsComplete Remission Acute Myelogenous Leukaemia Cytosine Arabinoside Blast Cell Count Remission Induction Rate
Unable to display preview. Download preview PDF.
- 2.Coltman CA Jr, Freireich EJ, Savage RA, Gehan EA (1979) Long-term survival of adults with acute leukaemia. Proc Am Soc Clin Onc 21: 389Google Scholar
- 6.Lister TA, Johnson SAN, Bell R, Henry G, Malpas JS (1981) Progress in acute myelogenous leukaemia. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukaemia 4. Springer, Berlin Heidelberg New York, p 38 (Haematology and Blood Transfusion, vol 26)Google Scholar
- 7.Mayer RJ, Coral FS, Rosenthal DS (to be published) Intensive post induction chemotherapy in the management of patients with acute myelogenous leukaemia. Cancer Treat RepGoogle Scholar
- 11.Preisler HD, Brecher M, Browman G, Early AP, Walker IR, Raza A, Freeman A (to be published) The treatment of acute myelocytic leukaemia in children and young adultsGoogle Scholar